Research Shows Drug Inhibits Mesothelioma Growth
A new drug might help successfully treat mesothelioma, one of the deadliest cancers, according to results from cell culture and mouse xenograft models of the disease.
Diagnosis & Disease Information
Tumor Weight and Volume May Improve Mesothelioma Staging Accuracy
Improvements in scoring the severity of mesothelioma could be achieved by considering both tumor weight and volume.
Immunotherapy drug pembrolizumab shows promise for patients with mesothelioma
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in approximately 76% of patients with pleural mesothelioma.
Investigational personalized cellular therapy tolerated well by patients
An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient’s own immune cells, genetically modified to target tumors.
High-dose radiotherapy doesn’t offer survival benefit in mesothelioma
Treatnent with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to phase II trial data.
PD-L1 a possible immunotherapy target in mesothelioma
Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.
Mesothelioma distinguished from noncancerous tissue by biomarkers
Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma and noncancerous pleural tissue with reactive mesothelial proliferations.
Novel cancer vaccine promising against ovarian cancer and mesothelioma
A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.
Radiation before surgery more than doubles mesothelioma survival
Treating mesothelioma with radiation before surgery resulted in a 3-year survival rate that was more than double compared with that of treating with surgery first, according to new research.
Rib cage lymph nodes are prognostic for mesothelioma
For the first time, researchers have shown the predictive power of a group of overlooked lymph nodes that could serve as a better tool to stage and ultimately treat patients with malignant pleural mesothelioma.
- Loading...
Loading...
Loading... 
Loading...